A 40-year-old woman with a recent history of carcinoma of the breast status post mastectomy and adjuvant chemotherapy one week ago presents for follow-up. She reports adequate pain control managed with the analgesic drug she was prescribed. Past medical history is significant for hepatitis C and major depressive disorder. The patient denies any history of smoking or alcohol use but says she is currently using intravenous heroin and has been for the past 10 years. However, she reports that she has been using much less heroin since she started taking the pain medication, which is confirmed by the toxicology screen. Which of the following is the primary mechanism of action of the analgesic drug she was most likely prescribed?
Q662
A 52-year-old man presents to his primary care physician complaining of a blistering rash in his inguinal region. Upon further questioning, he also endorses an unintended weight loss, diarrhea, polydipsia, and polyuria. A fingerstick glucose test shows elevated glucose even though this patient has no previous history of diabetes. After referral to an endocrinologist, the patient is found to have elevated serum glucagon and is diagnosed with glucagonoma. Which of the following is a function of glucagon?
Q663
A 6-year-old boy is brought to the pediatrician by his foster father because he is concerned about the boy's health. He states that at seemingly random times he will have episodes of severe difficulty breathing and wheezing. Upon questioning, the pediatrician learns that these episodes do not appear to be associated with exercise, irritants, or infection. The pediatrician suspects the child has a type of asthma that is associated with eosinophils. In this type of asthma, what is released by the eosinophils to cause bronchial epithelial damage?
Q664
A 22-year-old woman is brought to the emergency department by her roommate for unusual behavior. They were at a party where alcohol and recreational drugs were consumed, but her roommate is unsure of what she may have taken or had to drink. She is otherwise healthy and does not take any medications. The patient appears anxious. Her temperature is 37.5°C (99.5°F), pulse is 110/min, respiratory rate is 16/min, and blood pressure is 145/82 mmHg. Examination shows dry mucous membranes and bilateral conjunctival injection. Breath sounds are normal. The abdomen is soft and nontender. Further evaluation will most likely reveal which of the following?
Q665
A 40-year-old woman presents to her primary care physician with a 2-month history of joint pain and morning stiffness that improves through the course of the day. Her left knee also sometimes bothers her. She has taken ibuprofen and Tylenol without relief, and the pain is starting to upset her daily routine. On physical examination, the joints of her fingers and wrists are swollen and tender to touch. Her left knee also feels warm. The strength in both hands is reduced but the sensation is intact. On auscultation, the heart sounds are regular and the lungs are clear. Laboratory findings are presented below:
Hemoglobin 12.7 g/dL
Hematocrit 37.5%
Leukocyte count 5,500/mm3
Mean corpuscular volume 82.2 μm3
Platelet count 190,000/mm3
Erythrocyte sedimentation rate 45 mm/h
C-reactive protein 14 mg/dL
Anti-citrullinated protein antibody 43 (normal reference values: < 20)
Which of the following is the most appropriate treatment for this patient?
Q666
A 62-year-old woman presents to her primary care physician for her annual check-up. She has no current complaints and says that she has been healthy over the last year. Her past medical history is significant for obesity and diabetes that is well controlled on metformin. She does not smoke and drinks socially. Selected lab results are shown below:
High-density lipoprotein: 48 mg/dL
Low-density lipoprotein: 192 mg/dL
Triglycerides: 138 mg/dL
Given these results, the patient is placed on the drug that will be the best therapy for these findings. Which of the following is a potential side effect of this treatment?
Q667
A 19-year-old woman presents to the ED after multiple episodes of vomiting in the last 6 hours. The vomitus is non-bloody and non-bilious. The vomiting started shortly after she began having a throbbing, unilateral headache and associated photophobia. She has had several similar headaches in the past. Her vital signs are unremarkable. Which of the following is an appropriate therapy for this patient's vomiting?
Q668
A 56 year old female comes to the ED complaining of moderate right eye pain, headache, and acute onset of blurry vision, which she describes as colored halos around lights. She was watching a movie at home with her husband about an hour ago when the pain began. On physical exam of her right eye, her pupil is mid-dilated and unresponsive to light. Her right eyeball is firm to pressure. Intraocular pressure (IOP) measured with tonometer is elevated at 36mmHg. Which of the following is the most appropriate emergency treatment?
Q669
A 59-year-old woman comes to the clinic complaining of an intermittent, gnawing epigastric pain for the past 2 months. The pain is exacerbated with food and has been getting progressively worse. The patient denies any weight changes, nausea, vomiting, cough, or dyspepsia. Medical history is significant for chronic back pain for which she takes ibuprofen. Her father passed at the age of 55 due to pancreatic cancer. Labs were unremarkable except for a mild decrease in hemoglobin. What medication is most appropriate to be switched to from the current medication at this time?
Q670
An investigator is studying the metabolism of an experimental drug that is known to have first order kinetics. Immediately after administering an intravenous dose of the drug to a patient, the serum concentration is 60 U/L. 3 hours later, the serum concentration of the drug is 30 U/L. 9 hours after administration, the serum concentration of the drug is most likely to be which of the following?
Autonomic/CV Drugs US Medical PG Practice Questions and MCQs
Question 661: A 40-year-old woman with a recent history of carcinoma of the breast status post mastectomy and adjuvant chemotherapy one week ago presents for follow-up. She reports adequate pain control managed with the analgesic drug she was prescribed. Past medical history is significant for hepatitis C and major depressive disorder. The patient denies any history of smoking or alcohol use but says she is currently using intravenous heroin and has been for the past 10 years. However, she reports that she has been using much less heroin since she started taking the pain medication, which is confirmed by the toxicology screen. Which of the following is the primary mechanism of action of the analgesic drug she was most likely prescribed?
A. Pure antagonist at opioid receptors
B. Pure agonist at the µ-opioid receptor (Correct Answer)
C. Inhibits prostaglandin synthesis
D. Mixed agonist-antagonist at opioid receptors
E. Central action via blockade of serotonin reuptake
Explanation: ***Pure agonist at the µ-opioid receptor***
- Opioid analgesics, commonly prescribed for **post-mastectomy pain** and cancer-related pain, primarily exert their effects by acting as **pure agonists at the µ-opioid receptor**.
- This activation leads to profound **analgesia** by modulating pain perception and emotional response to pain in the central nervous system.
*Pure antagonist at opioid receptors*
- A **pure antagonist** would block opioid receptors and **reverse** the effects of opioid agonists, not provide analgesia.
- Such drugs are used to treat **opioid overdose** (e.g., naloxone) or to manage addiction by preventing opioid effects.
*Inhibits prostaglandin synthesis*
- This is the mechanism of action for **NSAIDs** (non-steroidal anti-inflammatory drugs), which primarily treat **mild to moderate pain** and inflammation.
- NSAIDs are generally insufficient for severe **post-surgical** or **cancer pain** of the magnitude experienced by this patient.
*Mixed agonist-antagonist at opioid receptors*
- Mixed agonist-antagonists provide analgesia by acting as agonists at some opioid receptors while acting as antagonists at others (e.g., **buprenorphine**).
- While they can provide pain relief, their use in acute severe pain is often limited, and they can sometimes **precipitate withdrawal** in patients chronically using full opioid agonists.
*Central action via blockade of serotonin reuptake*
- This is the primary mechanism of action for **antidepressants** (SSRIs) and some drugs used for **neuropathic pain** (e.g., tramadol with additional opioid action).
- While some antidepressants have analgesic properties, this mechanism alone is not typically the primary one for the potent pain relief needed post-mastectomy, which usually requires an **opioid**.
Question 662: A 52-year-old man presents to his primary care physician complaining of a blistering rash in his inguinal region. Upon further questioning, he also endorses an unintended weight loss, diarrhea, polydipsia, and polyuria. A fingerstick glucose test shows elevated glucose even though this patient has no previous history of diabetes. After referral to an endocrinologist, the patient is found to have elevated serum glucagon and is diagnosed with glucagonoma. Which of the following is a function of glucagon?
A. Inhibition of insulin release
B. Increased glycolysis
C. Increased lipolysis (Correct Answer)
D. Decreased glycogenolysis
E. Decreased ketone body production
Explanation: ***Increased lipolysis***
- **Glucagon** promotes the breakdown of **triglycerides** in adipose tissue into **fatty acids** and glycerol, which can then be used for energy.
- This metabolic effect contributes to **gluconeogenesis** by providing substrates, helping to raise blood glucose levels.
*Inhibition of insulin release*
- **Glucagon** generally **stimulates insulin release** in the presence of high blood glucose or certain amino acids, aiming to maintain glucose homeostasis.
- Its primary role is to counteract insulin's effects, not inhibit its secretion directly.
*Increased glycolysis*
- **Glucagon's** main function is to **increase blood glucose**, so it **inhibits glycolysis**, which is the breakdown of glucose for energy, to preserve glucose for other tissues.
- Instead, it promotes processes like **gluconeogenesis** and **glycogenolysis** to release glucose.
*Decreased glycogenolysis*
- **Glucagon** is a key hormone that **stimulates glycogenolysis**, the breakdown of stored **glycogen** in the liver, to release glucose into the bloodstream.
- This action helps to rapidly raise blood glucose levels, particularly during periods of fasting or low blood sugar.
*Decreased ketone body production*
- **Glucagon** generally **promotes ketone body production** (ketogenesis) in the liver by increasing the availability of fatty acids through lipolysis and shifting metabolism towards **fat oxidation**.
- This occurs when glucose is scarce, providing an alternative fuel source for the brain and other tissues.
Question 663: A 6-year-old boy is brought to the pediatrician by his foster father because he is concerned about the boy's health. He states that at seemingly random times he will have episodes of severe difficulty breathing and wheezing. Upon questioning, the pediatrician learns that these episodes do not appear to be associated with exercise, irritants, or infection. The pediatrician suspects the child has a type of asthma that is associated with eosinophils. In this type of asthma, what is released by the eosinophils to cause bronchial epithelial damage?
A. Major basic protein (Correct Answer)
B. IL-8
C. Interferon-gamma
D. IgM
E. IL-5
Explanation: ***Major basic protein***
- **Eosinophils** release several cytotoxic granule proteins, including **major basic protein (MBP)**, which directly damages bronchial epithelial cells, contributing to airway remodeling and hyperresponsiveness in eosinophilic asthma.
- MBP, along with **eosinophil cationic protein (ECP)**, **eosinophil peroxidase (EPO)**, and **eosinophil-derived neurotoxin (EDN)**, are key mediators of eosinophil-induced tissue injury.
*IL-8*
- **IL-8** (interleukin-8) is a **chemokine** primarily produced by macrophages and endothelial cells, which plays a crucial role in recruiting **neutrophils** to sites of inflammation.
- While important in inflammation, IL-8 is not directly released by eosinophils to cause bronchial epithelial damage.
*Interferon-gamma*
- **Interferon-gamma (IFN-γ)** is a cytokine predominantly produced by **T lymphocytes** and **natural killer (NK) cells**, playing a central role in antiviral and antitumor immunity.
- It is a key mediator of **Th1 immune responses** and is not released by eosinophils as a primary effector in bronchial damage.
*IgM*
- **IgM** is an **antibody** class, primarily involved in the primary immune response and activation of the complement system.
- Antibodies are produced by **B lymphocytes** and plasma cells, not by eosinophils, and their primary function is immune recognition rather than direct cytotoxic damage to epithelial cells.
*IL-5*
- **IL-5** (interleukin-5) is a cytokine that is critical for the **growth, differentiation, and activation of eosinophils** themselves; it is not released *by* eosinophils to cause damage.
- It is primarily produced by **Th2 lymphocytes** and mast cells, and is a key driver of eosinophilic inflammation, but it acts *on* eosinophils, rather than being an eosinophil-secreted damaging agent.
Question 664: A 22-year-old woman is brought to the emergency department by her roommate for unusual behavior. They were at a party where alcohol and recreational drugs were consumed, but her roommate is unsure of what she may have taken or had to drink. She is otherwise healthy and does not take any medications. The patient appears anxious. Her temperature is 37.5°C (99.5°F), pulse is 110/min, respiratory rate is 16/min, and blood pressure is 145/82 mmHg. Examination shows dry mucous membranes and bilateral conjunctival injection. Breath sounds are normal. The abdomen is soft and nontender. Further evaluation will most likely reveal which of the following?
A. Decreased appetite
B. Impaired reaction time (Correct Answer)
C. Respiratory depression
D. Pupillary constriction
E. Increased libido
Explanation: ***Impaired reaction time***
- The patient's presentation with **anxiety**, **tachycardia**, **hypertension**, **dry mucous membranes**, and **conjunctival injection** are consistent with acute **cannabis intoxication**.
- **Cannabis use** is known to cause dose-dependent **psychomotor impairment** including **slowed reaction time**, impaired judgment, and decreased coordination, making tasks like driving dangerous.
- This is the most clinically significant finding that would be revealed upon further evaluation (e.g., through psychomotor testing or assessment).
*Decreased appetite*
- While chronic cannabis use can increase appetite (the "munchies"), acute intoxication does not typically lead to decreased appetite.
- Cannabis is more commonly associated with increased appetite rather than decreased appetite, making this option incorrect.
*Respiratory depression*
- **Opioid overdose** or severe sedative intoxication would typically present with **respiratory depression**, which is not seen in this patient (respiratory rate is normal at 16/min).
- Cannabis intoxication generally causes either no significant change in respiratory rate or, less commonly, slight bronchodilation, not respiratory depression.
*Pupillary constriction*
- **Pupillary constriction** (miosis) is a classic sign of **opioid intoxication** or organophosphate poisoning.
- Cannabis intoxication more commonly causes **pupillary dilation** (mydriasis) or no significant change, not constriction.
*Increased libido*
- While some individuals may report altered sexual experiences under the influence of cannabis, it is not a consistent or clinically significant feature of acute intoxication in an emergency setting.
- This is not an objective finding that would likely be revealed upon further evaluation in the emergency department.
Question 665: A 40-year-old woman presents to her primary care physician with a 2-month history of joint pain and morning stiffness that improves through the course of the day. Her left knee also sometimes bothers her. She has taken ibuprofen and Tylenol without relief, and the pain is starting to upset her daily routine. On physical examination, the joints of her fingers and wrists are swollen and tender to touch. Her left knee also feels warm. The strength in both hands is reduced but the sensation is intact. On auscultation, the heart sounds are regular and the lungs are clear. Laboratory findings are presented below:
Hemoglobin 12.7 g/dL
Hematocrit 37.5%
Leukocyte count 5,500/mm3
Mean corpuscular volume 82.2 μm3
Platelet count 190,000/mm3
Erythrocyte sedimentation rate 45 mm/h
C-reactive protein 14 mg/dL
Anti-citrullinated protein antibody 43 (normal reference values: < 20)
Which of the following is the most appropriate treatment for this patient?
A. Methotrexate (Correct Answer)
B. Hydroxychloroquine
C. Infliximab
D. Etanercept
E. Ibuprofen
Explanation: ***Methotrexate***
- This patient presents with **symmetrical polyarthritis** (fingers, wrists, knee), **morning stiffness**, elevated **ESR and CRP**, and a **positive anti-citrullinated protein antibody**, all highly suggestive of **rheumatoid arthritis (RA)**.
- **Methotrexate** is considered the **first-line disease-modifying antirheumatic drug (DMARD)** for RA due to its efficacy in reducing joint inflammation and preventing joint damage.
*Hydroxychloroquine*
- While used in RA, **hydroxychloroquine** is generally reserved for **mild RA** or for patients who cannot tolerate methotrexate, and it is less effective for moderate to severe disease.
- This patient's symptoms are beginning to upset her daily routine, indicating more than mild disease, and she has **high inflammatory markers** (ESR 45, CRP 14) and a **positive anti-CCP antibody**, suggesting a more aggressive course.
*Infliximab*
- **Infliximab** is a biologic DMARD (TNF-alpha inhibitor) used for RA, but it is typically reserved for patients with a **suboptimal response to methotrexate** or other conventional DMARDs.
- It is not usually prescribed as a first-line treatment due to its higher cost and potential side effects compared to methotrexate.
*Etanercept*
- **Etanercept** is another biologic DMARD (TNF-alpha inhibitor) used for RA that is also typically reserved for patients who have had an **inadequate response to methotrexate** or other non-biologic DMARDs.
- Like infliximab, it is not a first-line agent, and initial management begins with conventional DMARDs.
*Ibuprofen*
- **Ibuprofen** is a **nonsteroidal anti-inflammatory drug (NSAID)** that provides symptomatic relief from pain and inflammation but does **not modify the disease course** or prevent joint damage in RA.
- The patient has already tried ibuprofen without relief, and NSAIDs are used as adjuncts to DMARDs, not as monotherapy for chronic inflammatory conditions like RA.
Question 666: A 62-year-old woman presents to her primary care physician for her annual check-up. She has no current complaints and says that she has been healthy over the last year. Her past medical history is significant for obesity and diabetes that is well controlled on metformin. She does not smoke and drinks socially. Selected lab results are shown below:
High-density lipoprotein: 48 mg/dL
Low-density lipoprotein: 192 mg/dL
Triglycerides: 138 mg/dL
Given these results, the patient is placed on the drug that will be the best therapy for these findings. Which of the following is a potential side effect of this treatment?
A. Gallstones
B. Pruritus
C. Gastrointestinal upset
D. Malabsorption
E. Hepatotoxicity (Correct Answer)
Explanation: ***Hepatotoxicity***
- This patient has significantly elevated **LDL cholesterol**, necessitating treatment with a **statin drug** (HMG-CoA reductase inhibitor).
- A known, though rare, side effect of statin therapy is **hepatotoxicity**, which requires monitoring of **liver enzymes**.
*Gallstones*
- **Fibrates** are a class of lipid-lowering drugs that can increase the risk of **gallstone formation** by increasing cholesterol secretion into bile.
- While fibrates lower triglycerides, they are not the primary treatment for significantly elevated LDL as seen in this patient.
*Pruritus*
- **Niacin** (vitamin B3) is a lipid-lowering agent known for causing significant **cutaneous flushing and pruritus** due to prostaglandin release.
- Niacin is not the first-line treatment for high LDL, especially given the side effect burden.
*Gastrointestinal upset*
- **Bile acid sequestrants** (e.g., cholestyramine, colestipol) often cause gastrointestinal side effects such as **constipation, bloating, and nausea**.
- These drugs are typically used in combination with statins or as an alternative in statin-intolerant patients, but statins are the initial choice for high LDL.
*Malabsorption*
- **Ezetimibe**, a cholesterol absorption inhibitor, can rarely cause gastrointestinal discomfort, but it is not typically associated with widespread **malabsorption of nutrients**.
- Its primary role is to block cholesterol absorption in the small intestine, leading to a modest reduction in LDL, often as an add-on therapy.
Question 667: A 19-year-old woman presents to the ED after multiple episodes of vomiting in the last 6 hours. The vomitus is non-bloody and non-bilious. The vomiting started shortly after she began having a throbbing, unilateral headache and associated photophobia. She has had several similar headaches in the past. Her vital signs are unremarkable. Which of the following is an appropriate therapy for this patient's vomiting?
A. Ergonovine
B. Propranolol
C. Chlorpromazine (Correct Answer)
D. Amitriptyline
E. Calcium channel blockers
Explanation: ***Chlorpromazine***
- Patients experiencing **acute migraine attacks with severe nausea and vomiting** can benefit from antiemetics, particularly those with additional dopamine antagonist properties like chlorpromazine.
- This medication helps in reducing both the **headache severity** and the associated emesis due to its broader neurological effects on **dopaminergic pathways**.
*Ergonovine*
- **Ergonovine is an ergot alkaloid** primarily used to prevent or treat **postpartum hemorrhage** by inducing uterine contractions.
- It is not indicated for the treatment of migraine-associated nausea and vomiting and could potentially worsen symptoms or cause **vasospasm**.
*Propranolol*
- **Propranolol is a beta-blocker primarily used for migraine prophylaxis**, meaning it helps prevent migraines from occurring.
- It is not effective for **acute treatment of active migraine headaches** or for the immediate relief of associated vomiting.
*Amitriptyline*
- **Amitriptyline is a tricyclic antidepressant** commonly prescribed for **migraine prophylaxis** in patients with frequent attacks.
- Like propranolol, it is a **preventive medication** and is not suitable for the acute management of migraine symptoms, including vomiting.
*Calcium channel blockers*
- **Calcium channel blockers** like verapamil are sometimes used for **migraine prophylaxis**, particularly in patients who do not respond to or tolerate other preventive therapies.
- They are not considered a first-line treatment for **acute migraine attacks or associated vomiting**.
Question 668: A 56 year old female comes to the ED complaining of moderate right eye pain, headache, and acute onset of blurry vision, which she describes as colored halos around lights. She was watching a movie at home with her husband about an hour ago when the pain began. On physical exam of her right eye, her pupil is mid-dilated and unresponsive to light. Her right eyeball is firm to pressure. Intraocular pressure (IOP) measured with tonometer is elevated at 36mmHg. Which of the following is the most appropriate emergency treatment?
A. Laser peripheral iridotomy
B. Epinephrine ophthalmic solution
C. Anti-cholinergic ophthalmic solution
D. NSAID ophthalmic solution
E. Timolol ophthalmic solution (Correct Answer)
Explanation: ***Timolol ophthalmic solution***
- The patient presents with symptoms and signs consistent with **acute angle-closure glaucoma** (AAGC), including acute eye pain, headache, colored halos, mid-dilated non-reactive pupil, firm eyeball, and elevated IOP. **Timolol** is a **beta-blocker** that reduces aqueous humor production, thereby lowering intraocular pressure.
- Emergency treatment for AAGC focuses on rapidly lowering IOP to prevent permanent vision loss, often involving a combination of topical medications like beta-blockers (e.g., timolol), **alpha-agonists**, and **carbonic anhydrase inhibitors**, along with systemic agents if needed.
*Laser peripheral iridotomy*
- This is a definitive treatment for AAGC, creating an opening in the iris to equalize pressure between the anterior and posterior chambers; however, it is typically performed **after initial medical management** has reduced the IOP.
- While it addresses the underlying anatomical cause, it is not the immediate first-line emergency treatment to acutely lower a critically high IOP.
*Epinephrine ophthalmic solution*
- Epinephrine can cause **pupil dilation (mydriasis)**, which can further exacerbate angle closure in AAGC by pushing the iris into the angle.
- Therefore, it is **contraindicated** in acute angle-closure glaucoma.
*Anti-cholinergic ophthalmic solution*
- Anti-cholinergic agents like atropine cause **pupil dilation (mydriasis)** and relaxation of the ciliary muscle, pulling the iris posteriorly and potentially worsening angle closure.
- These are **contraindicated** in acute angle-closure glaucoma as they can worsen the condition by further narrowing the anterior chamber angle.
*NSAID ophthalmic solution*
- NSAID ophthalmic solutions are primarily used to treat **ocular inflammation** and **pain** in conditions such as postoperative inflammation or allergic conjunctivitis.
- They do not directly lower intraocular pressure and are therefore not an appropriate emergency treatment for acute angle-closure glaucoma.
Question 669: A 59-year-old woman comes to the clinic complaining of an intermittent, gnawing epigastric pain for the past 2 months. The pain is exacerbated with food and has been getting progressively worse. The patient denies any weight changes, nausea, vomiting, cough, or dyspepsia. Medical history is significant for chronic back pain for which she takes ibuprofen. Her father passed at the age of 55 due to pancreatic cancer. Labs were unremarkable except for a mild decrease in hemoglobin. What medication is most appropriate to be switched to from the current medication at this time?
A. Naproxen
B. Ranitidine
C. Aspirin
D. Acetaminophen
E. Omeprazole (Correct Answer)
Explanation: ***Omeprazole***
- The patient's symptoms of **gnawing epigastric pain** exacerbated by food, along with a history of chronic ibuprofen use and mild anemia, strongly suggest a **peptic ulcer**.
- **Omeprazole**, a proton pump inhibitor (PPI), is the most effective medication for healing ulcers and preventing their recurrence by reducing gastric acid production.
*Naproxen*
- **Naproxen** is a non-steroidal anti-inflammatory drug (NSAID), similar to ibuprofen, and would likely worsen the patient's symptoms by further inhibiting prostaglandin synthesis necessary for gastric mucosal protection.
- Continuing an NSAID without gastroprotection would increase the risk of ulcer complications, such as bleeding.
*Ranitidine*
- **Ranitidine** is an H2-receptor antagonist, which reduces stomach acid, but it is generally less potent than PPIs like omeprazole for treating and healing ulcers, especially in cases of NSAID-induced gastropathy.
- Its efficacy for advanced or severe peptic ulcer disease is inferior to that of PPIs.
- Note: Ranitidine was withdrawn from the US market in 2020 due to NDMA contamination; alternative H2 blockers include famotidine.
*Aspirin*
- **Aspirin** is an NSAID with significant antiplatelet effects and is well-known to cause and exacerbate peptic ulcers and gastrointestinal bleeding.
- Switching to aspirin would be contraindicated in the presence of strong evidence suggesting active peptic ulcer disease.
*Acetaminophen*
- **Acetaminophen** (paracetamol) is an analgesic that does not have significant anti-inflammatory properties and is not associated with gastric irritation or ulcer formation.
- While it could be used for pain relief, it does not address the underlying issue of peptic ulcer disease or provide gastroprotection, making it an inadequate switch for effective management.
Question 670: An investigator is studying the metabolism of an experimental drug that is known to have first order kinetics. Immediately after administering an intravenous dose of the drug to a patient, the serum concentration is 60 U/L. 3 hours later, the serum concentration of the drug is 30 U/L. 9 hours after administration, the serum concentration of the drug is most likely to be which of the following?
A. 5 U/L
B. 0 U/L
C. 15 U/L
D. 7.5 U/L (Correct Answer)
E. 3.75 U/L
Explanation: ***7.5 U/L***
- The drug follows **first-order kinetics**, meaning a constant fraction of the drug is eliminated per unit time, resulting in a constant **half-life**.
- The concentration halved from 60 U/L to 30 U/L in 3 hours, indicating a **half-life of 3 hours**. Thus, after another 3 hours (total 6 hours), the concentration would be 15 U/L, and after yet another 3 hours (total 9 hours), it would be **7.5 U/L**.
*5 U/L*
- This answer suggests a slower rate of elimination than calculated for first-order kinetics with a 3-hour half-life.
- If the half-life were longer than 3 hours, then 5 U/L might be a plausible concentration at 9 hours.
*0 U/L*
- For drugs following **first-order kinetics**, the concentration approaches zero asymptotically and never truly reaches zero within a finite timeframe, unless the total elimination has significantly exceeded multiple half-lives.
- This answer indicates complete elimination, which is incorrect for a drug still undergoing elimination after 9 hours.
*15 U/L*
- This would be the concentration at 6 hours (two half-lives) after administration, not 9 hours (three half-lives).
- It would occur if only two half-life periods had passed instead of three.
*3.75 U/L*
- This value represents the concentration after a fourth half-life (12 hours), not three half-lives (9 hours).
- This would be the concentration after 12 hours had passed from the initial administration.